F
Firebrick Pharma Ltd
ASX:FRE
Firebrick Pharma Ltd
ASX:FRE
Price:
0.054
AUD
-12.9%
Market Closed
Market Cap:
AU$13.6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Firebrick Pharma Ltd
Accumulated Depreciation
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Firebrick Pharma Ltd
Accumulated Depreciation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Firebrick Pharma Ltd
ASX:FRE
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Accumulated Depreciation
-AU$627.1k
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Accumulated Depreciation
-AU$61.2m
|
CAGR 3-Years
22%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Accumulated Depreciation
-AU$547.3k
|
CAGR 3-Years
-62%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
No Stocks Found
Firebrick Pharma Ltd
Glance View
Firebrick Pharma Ltd. engages in the development and manufacture of pharmaceutical products. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-01-28. The firm is focused to develop Nasodine, a nasal spray that contains the broad spectrum antimicrobial agent called povidone-iodine. The firm is engaged in product formulation, packaging and manufacturing development. Nasodine nasal spray medicine targets the cause of colds, where they start in the nose. Its nasal spray is responsible for respiratory infections, such as the common cold. The firm's Series C funding, Phase III trial has been completed.
FRE
Intrinsic Value
0.012
AUD
Overvaluation 78%
F
